Labcorp Holdings LH Biopharma Laboratory Services — Depreciation

Other segment segments

Similar metrics at other companies

TMOLaboratory Products and Biopharma Services — Depreciation of property, plant and equipment

$186M+8.1%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Depreciation

$119K-76.8%

MLABBiopharmaceutical Development — Cost Of Goods And Services Sold Depreciation

$65K-13.3%

ASHLife Sciences — Depreciation

$9M-59.1%

PTCTLife Science — Depreciation

$3.81M+10.1%

BAXPharmaceuticals — Depreciation

$16M0.0%

Questions, answered.

What is Labcorp Holdings's biopharma laboratory services — depreciation?

Labcorp Holdings (LH) reported biopharma laboratory services — depreciation of $28.6M in Q1 2026.

How has Labcorp Holdings's biopharma laboratory services — depreciation changed year-over-year?

Labcorp Holdings's biopharma laboratory services — depreciation decreased by 0.0% year-over-year, from $28.6M to $28.6M.

What is the long-term trend for Labcorp Holdings's biopharma laboratory services — depreciation?

Over 3 years (2022 to 2025), Labcorp Holdings's biopharma laboratory services — depreciation has grown at a 0.9% compound annual growth rate (CAGR), from $112.8M to $116M.

What does biopharma laboratory services — depreciation mean?

This represents the systematic allocation of the cost of tangible assets, such as laboratory equipment and facilities, over their useful lives within the Biopharma Laboratory Services segment. It reflects the capital intensity of the segment's operations.